ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Opportunity lost

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Jan 13, 2022 4:01pm

90 Views

Post# 34314427

RE:RE:RE:RE:Opportunity lost

Lol

So 2 million shares traded today and no uptick in SP. Very frustrating.

M101, I see your point with the pp holders selling their shares, but why do it now and not when SP was at 0.17-0.22 for 7 months? Plus, after Gene's presentation, isn't that where we're supposed to be heading imminently?

Any clue what the balance is of the unexercised warrants?

I kind of get that feeling that some big boys are playing this stock like a 4 dollar banjo.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1